The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×3•Originally published 5 May 2026•Updated 7 May 2026•

1 min read

Xencor Q1 Results Show Wider Loss and Sharp Revenue Miss Below Estimates

Key Facts

1Alkermes reported a quarterly loss of $0.4 per share, beating the Zacks Consensus Estimate of a $0.57 loss.

2The current results compare to earnings of $0.13 per share reported in the same quarter a year ago.

Xencor (XNCR) reported disappointing financial results for the first quarter, posting a loss of $1.71 per share, significantly wider than the analyst consensus of a $0.65 loss. The company generated $4.52 million in revenue, missing Wall Street estimates by a substantial 75.38%. These results contrast with the broader operational focus seen in peers like Neurocrine Biosciences and the growth trends of Axsome Therapeutics. The sharp revenue miss and higher-than-expected losses highlight significant challenges in the company's current financial trajectory. Investors are now closely evaluating Xencor's ability to manage costs and improve commercial performance in a competitive biotech landscape. This earnings miss serves as a critical update for market participants assessing the stock's valuation and future guidance.

28 days ago

Version History

2 additional sources confirmed this story

Version 328 days ago

What changed: The story was updated to include Xencor's weak financial performance data, specifically the wider-than-expected loss per share and the significant revenue miss compared to analyst estimates.

Version 229 days ago

What changed: The story was updated to include Neurocrine's (NBIX) Q1 2026 earnings results and their performance relative to analyst estimates.

Version 129 days ago

What changed: Updated the story to include Axsome Therapeutics' Q1 financial performance, highlighting a 57% revenue jump and widening losses.